Table 1.

Guidance questions to be considered

1. Which VTE patients are (and are not) good candidates for DOAC therapy?

2. How should DOACs be initiated for VTE treatment?

3. How should the anticoagulant activity of DOACs be measured?

4. How should VTE patients who require temporary interruption of DOAC therapy be managed?

5. How should patients with DOAC drug–drug interactions be managed?

6. How should patients transition between anticoagulants?

7. How should DOAC-associated bleeding be managed?

8. What is an appropriate care transitions and follow-up strategy for VTE patients on DOAC therapy?

9. How can patients enhance safety and efficacy of their DOAC therapy?